Haematopathology like nowhere else!
From Saturday 17 to Thursday 22 September 2022 the hemepath community will gather to address current contentious diagnostic issues and shape the direction of future research.
- Advance hemepath science and your career
- Benefit from presentations covering the most recent discoveries in hemepath prevention, diagnosis, and treatment
- Learn beyond your field or interest
Bone marrow symposium
The bone marrow symposium will be focused on “Novel frontiers in molecular diagnosis of myeloid neoplasms: biomarkers and integrative prognostic models in myeloid diseases” the aim is to understand how a proper integration of morphological, clinical and molecular data is essential in reaching a correct diagnosis and to guide treatment decision. Topics to be discussed will include the prognostic and clinical significance of new genetic markers or combinations of genetic markers, the paradigm of targeting oncogenic tyrosine kinase signaling in myeloid neoplasia, and the importance of doing genetic analysis in unusual presentation of myeloid diseases or as marker of disease progression.
Bone marrow workshop
Session topics include:
- Emerging/provisional entities
- Myeloma/immunosecretory diseases/Amyloidosis
- Unusual/other neoplasms mainly involving the BM
David Mason lecture
Oncogenic mechanisms in the development of T-cell lymphomas
Institute of Cancer Genetics, Columbia University, NY, USA
The lymphoma symposium will be devoted to “Novel frontiers in molecular diagnosis of lymphoma: biomarkers and integrative prognostic models”. It will explore how best to integrate into our daily clinical practice the plethora of new technologies that help us understand lymphoma biology and are key to pathological classification. The clinical impact of innovative technologies in the management of lymphoma patients will be discussed.
- New horizons in clonality detection
- NGS Panel-sequencing for mutations in a diagnostic setting
- Lymphomas defined by structural chromosomal alterations
- The clinical impact of innovative technologies in the management of lymphoma patients
- Recent advances
Provisional and emerging disease entities
The workshop will cover the most controversial issues in haematopathology:
- Emerging entities and molecular algorithms in large B-cell lymphoma
Examples of LBCL-IRF4 rearrangement and its differential diagnosis, Burkitt-like with 11q alterations and its differential diagnosis. Molecular algorithms applied to DLBCL, NOS
- Cavity associated lymphomas
Examples include HHV8-positive and negative effusion-related lymphomas, DLBCL associated with chronic inflammation, fibrin-associated DLBCL, and other B-cell lymphomas presenting in body cavities or cystic spaces, as well as cavity-based T-cell lymphoproliferations such as breast implant associated ALCL.
- The waste basket of marginal zone lymphomas
Examples include nodal MZL, nodal pediatric, splenic marginal zone lymphoma and well documented cases of transformed MZL (BN2 group)
- Cytotoxic T-cell lymphoma (excluding skin) and EBV-positive nodal T/NK-cell lymphomas (excluding extranodal NK/T cell lymphomas, nasal type)
- Lymphomas with a T-follicular helper cell phenotype
Examples include cases illustrating the borderlines with PTCL, NOS, and reactive conditions, as well as the association with clonal hematopoesis (CHIP)
“Meet the Professor” sessions (pre-registration required)
One of the highlights of the scientific programme, the “Meet the Professor” sessions, offer you the chance of a LIVE informal meeting with some of the biggest names in the field.
Each delegate can only book one “Meet the Professor” session. Please note that the number of attendees is limited.
* A maximum of 35 seats is available per session. 25 places per session will be allocated at the time of first registration and an additional 10 seats per session on the day notifications of acceptance for cases and abstracts are sent.
Get the latest updates!
Subscribe to our newsletter to receive the latest news and updates about EAHP-SH! You can unsubscribe from the mailing list at any time.